Robust neutralising activity and activation of neutrophil cytotoxic responses mediated by antibodies targeting the HTLV-1 envelope glycoprotein by Kuo, Chien-wen et al.
                                                              
University of Dundee
Robust neutralising activity and activation of neutrophil cytotoxic responses mediated
by antibodies targeting the HTLV-1 envelope glycoprotein
Kuo, Chien-wen; Tulloch, Lindsay; Brighty, David W.
Published in:
Retrovirology
DOI:
10.1186/1742-4690-8-S1-A170
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Kuo, C., Tulloch, L., & Brighty, D. W. (2011). Robust neutralising activity and activation of neutrophil cytotoxic
responses mediated by antibodies targeting the HTLV-1 envelope glycoprotein. Retrovirology, 8(Supplement 1),
[A170]. https://doi.org/10.1186/1742-4690-8-S1-A170
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
MEETING ABSTRACT Open Access
Robust neutralising activity and activation of
neutrophil cytotoxic responses mediated by
antibodies targeting the HTLV-1 envelope
glycoprotein
Chien-Wen Kuo, Lindsay Tulloch, David W Brighty*
From 15th International Conference on Human Retroviruses: HTLV and Related Viruses
Leuven and Gembloux, Belgium. 5-8 June 2011
Infection of human cells by Human T-cell leukaemia
virus (HTLV-1) is mediated by the viral envelope glyco-
proteins. The gp46 surface glycoprotein binds to a cell
surface receptors, including heparan sulphate proteogly-
cans, neuropilin-1, and Glut-1, allowing the transmem-
brane glycoprotein to initiate fusion of the viral and
cellular membranes. The envelope glycoproteins are
recognised by neutralising antibodies and cytotoxic T
lymphocytes following a protective immune response,
and therefore represent attractive components for an
HTLV-1 vaccine. Here we begin to explore the immu-
nological properties of recombinant SU as a potential
subunit vaccine candidate. We have used a soluble
recombinant gp46 fused to the Fc-region of human IgG
(sRgp46-Fc) as an immunogen to vaccinate mice and
generate monoclonal antibodies (mAbs) targeting SU.
The recombinant SU protein is highly immunogenic,
inducing high titre antibody responses to the immuno-
gen and facilitating selection of hybridomas that secrete
anti-SU mAbs. Many of these mAbs recognise envelope
expressed by HTLV-1 infected cells and these antibodies
strongly stimulate neutrophil-mediated cytotoxic
responses. Moreover, several of the mAbs directly and
robustly antagonise envelope-mediated fusion and neu-
tralize pseudovirus infectivity. While antibodies targeting
either the receptor-binding domain or C-terminal
domain of SU exhibit anti-viral activity, the most
potently neutralizing mAbs tend to recognise epitopes
that cluster in the N-terminal receptor-binding domain
of SU. Thus, our data demonstrate that recombinant
forms of SU possess immunological features that are of
direct utility to subunit vaccine design.
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